Abstract
Background Understanding user engagement with conversational agents (CAs) in mobile health apps is crucial for improving sustained usage. We analyzed CA interactions in a mobile health app to identify usage patterns and potential barriers.
Materials and Methods Retrospective data from 100,571 active users of the Albert Health app in 2022 were analyzed. Interactions with CA were categorized by demographics (gender and age), interaction type (health information, medication-related, clinical parameters, and non-clinical), and engagement method (text, voice). Descriptive statistics were used to identify trends and patterns in app usage.
Results Out of the active users, 19,051 (18.9%) engaged with the CA. The majority were female (61%), with 43% aged 30-45 years and 23% older than 45 years. The analysis showed that 94.5% engaged in general health management, while 5.3% used disease-specific programs. Average usage per user was highest in cardiovascular and respiratory diseases. Interaction types varied, with health information and medication-related interactions. The varied messaging behavior suggests different user engagement levels, with some users seeking quick information and others engaging more deeply for health management. Engagement was high initially but decreased over time.
Discussion This study provides insights into user interactions with a healthcare CA, highlighting a preference for general health management and diverse usage patterns. The significant number of single-session users indicates potential barriers to sustained engagement, highlighting the need for strategies to enhance user experience and retention. Future research should investigate the CA’s performance, effectiveness and extend observations to broader healthcare contexts by using large language models.
Competing Interest Statement
SC, MD, ZPP and AY are employees of Albert Health
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study received approval from the Biruni University Ethics Committee (Approval number: 2023/83-18)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are not available due to ethical committee approval
